Analysts Have Made A Financial Statement On Puma Biotechnology, Inc.'s ( NASDAQ:PBYI) First-Quarter Report
Puma Biotechnology (NASDAQ:PBYI) investors are sitting on a loss of 86% if they invested five years ago | Nasdaq
![Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space ( NASDAQ:PBYI) | Seeking Alpha Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space ( NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181263174/image_1181263174.jpg?io=getty-c-crop-4-3)
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space ( NASDAQ:PBYI) | Seeking Alpha
![Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space ( NASDAQ:PBYI) | Seeking Alpha Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space ( NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/uploads/2021/4/25/saupload_zys-A0tTqP8PWlrKLGfU8XarhV75bml0GYT6UZXNdTCeU2AaCXx_644abKUiyEdFCXTOTLutlWDqvkveyTHWK0PYMs5db5WuIcg_P_sz1aH9ATSAfg5L9AuFRgTc-G3-cE9vOVv7.png)
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space ( NASDAQ:PBYI) | Seeking Alpha
![Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha](https://static3.seekingalpha.com/uploads/sa_presentations/448/67448/slides/1.jpg?1615833116)
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
![Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - Defense World Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - Defense World](https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=500&h=300&zc=2&src=https://www.marketbeat.com/logos/puma-biotechnology-inc-logo.jpg)
Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - Defense World
![Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America](https://www.pint-pharma.com/images/st_metanic/blog/blog-2.png)